Odapipam Explained

Class:	Dopamine D1 receptor antagonist
Cas Number:	131796-63-9
Pubchem:	132421
Chemspiderid:	116932
Unii:	847PQF7ZN6
Chembl:	2106649
Synonyms:	NNC 01-0756; NNC-01-0756; NNC-010756; NNC010756; NNC01-0756; NNC-756; NNC756; NNC 0756; NNC0756; NO-756; NO756
Iupac Name:	(5S)-8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
C:	19
H:	20
Cl:	1
N:	1
O:	2
Smiles:	CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC4=C3OCC4)O)Cl
Stdinchi:	1S/C19H20ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
Stdinchikey:	SKMVRXPBCSTNKE-MRXNPFEDSA-N

Odapipam (; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D₁ receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.^{[1] [2]}

It has more than 5,000-fold selectivity for the dopamine D₁ receptor (K_i = 0.17nM) over the dopamine D₂ receptor (K_i = 942nM).^[3] Its affinities for other dopamine receptors, such as the dopamine D₅ receptor, were not reported. In addition to the dopamine D₁ receptor, odapipam showed relatively high affinity for the serotonin 5-HT₂ receptor (K_i = 4.5nM; 26-fold lower than for the D₁ receptor).

The drug was first described in the scientific literature by 1988.^{[4] [5]}

See also

• Berupipam (NNC 22-0010)
• Ecopipam (SCH-39166)
• NNC 01-0687 (ADX-10061)
• SCH-23390

Notes and References

1. Shen WW . A history of antipsychotic drug development . Compr Psychiatry . 40 . 6 . 407–414 . 1999 . 10579370 . 10.1016/s0010-440x(99)90082-2 .
2. Seamans JK, Yang CR . The principal features and mechanisms of dopamine modulation in the prefrontal cortex . Prog Neurobiol . 74 . 1 . 1–58 . September 2004 . 15381316 . 10.1016/j.pneurobio.2004.05.006 .
3. Neumann J, Hofmann B, Dhein S, Gergs U . Role of Dopamine in the Heart in Health and Disease . Int J Mol Sci . 24 . 5 . March 2023 . 5042 . 36902474 . 10003060 . 10.3390/ijms24055042 . free .
4. Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB . NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists . Eur J Pharmacol . 219 . 1 . 45–52 . August 1992 . 1397049 . 10.1016/0014-2999(92)90578-r .
5. Waddington JL . Functional interactions between D-1 and D-2 dopamine receptor systems: their role in the regulation of psychomotor behaviour, putative mechanisms, and clinical relevance . J Psychopharmacol . 3 . 2 . 54–63 . January 1989 . 22156499 . 10.1177/026988118900300202 .